Why You Should Buy Capital One

PAULSON & COIn a time of economic uncertainty and significant personal deleveraging, it may be hard to be bullish on a company that derives 60% of revenues from credit card loans and 30% from consumer loans. However, on the back of the February Comprehensive Capital Analysis and Review (CCAR), which stress tests and reviews capital plans of the 19 largest U.S. bank holding companies, and strong credit metrics, we feel Capital One (NYSE: COF) is a cut above the rest as do hedge fund managers Eddie Lampert, John Paulson, Andreas Halvorsen, and John Horseman.

In February, COF reported strong credit metrics with declines in both net charge-offs (NCOs) and delinquencies for US cards. Net charge-offs refer to debts that are determined to be uncollectible and thus written off. Delinquencies recognized if a cardholder has not made the minimum payment 30 days after the payment was due. US Card NCOs decreased to 3.84% from 4.08% in January. US card delinquencies decreased to 3.62%. We view this data favorably as a part of a longer term trend of improving consumer credit.

The big news surrounding COF is its recent completion of a $1.25 billion capital raise for the HSBC USA card business transaction. Now that the ING Direct and HSBC transactions are complete, COF will focus its attention on managing the integration costs and executing its plans to increase infrastructure. Previously, there was some uncertainty regarding the amount and source of the financing. Now the main uncertainty that remains surround ING Group (NYSE: ING) selling its 9.7% stake in COF (worth an estimated $3 billion). Once there is more visibility on that issue, the overhang on the stock should be eliminated.

Our thoughts surrounding the deals are positive. ING Direct will add approximately $200 billion in deposits to COF, making it one of the largest depositories in the US. The strong depository franchise mitigates our concerns regarding COF’s sensitivity to lower spending and weakening credit. The HSBC acquisition will add approximately $30 billion of credit card receivables, increasing the existing US card portfolio by over 50%.

The decline in interest rates since the announcement of both deals has proved favorable: the fair value of ING Direct assets has appreciated since the announcement last June now that loans are delivering yields above prevailing market rates as has the HSBC Card portfolio since the announcement last August. On the HSBC portfolio, COF expects to take a $710 million markup and a $900 million credit mark down on delinquent loans. On the ING Direct portfolio, COF expects to take a mark down of $429 million, notably lower than management’s initial guidance of $1.7 billion. In our view, the ING Direct and HSBC card acquisitions will be the largest driver of earnings and will allow management some flexibility in managing expense ratios.

From a valuation standpoint, we find COF attractive, trading at ~7.9x 2013 earnings.  This is below American Express (NYSE: AXP), which trades at ~11.8x, Discover Financial Services (NYSE: DFS) which trades at ~9.1x, and the larger bank group which trades at ~10.2x. AXP, DFS and COF had minimum Tier 1 Common capital ratios above the 5% minimum—COF reported 7.8%. However, the effect of Basel II/III post-mergers is yet to be determined. COF assumed approximately $2.5 billion of non-agency RMBS from ING. Basel III capital requirements may force COF to increase its risk weighted credit card assets, which will be a major determinant as to whether COF will be in a position to return cash to shareholders. However, we are optimistic that earnings accretion from the two deals will put COF in a good position to do so. AXP and DFS announced share repurchase plans, neither of which the Fed had objections to: AXP plans share repurchases of up to $4 billion in 2012 and plans to raise its quarterly dividend up 11%. DFS announced a new share repurchase program of up to $2 billion. Though COF shares up 30% YTD, we see potential for additional capital appreciation if management executes appropriately with regards to a smooth integration of ING Direct and HSBC Card operations, increasing loan growth, and focusing on customer retention.

Biotech Insider Alert - $6 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Click here to Read Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 74 percentage points in 2.5 years. Our beta is only 1.2 (download a FREE newsletter and see the details inside)

Lists

Best Selling Magazines in the World

Shortest People in History

The Most Celebrated Holidays in the World

Most Expensive Handbag Brands in the World

Top Selling Comic Book Issues of this Century

The Most Powerful Women in Politics

Best Paid DJs

Most Rebellious Female Artists

Best Paid TV Actresses of 2014

Best Paid Actors of 2014

Most Expensive Horses in the World

Tallest People Ever

Most Encouraging Feminist Celebrities

Best Paid Supermodels of 2014

Top 10 Suburbs for Retirement in 2015

10 Wealthiest Cities in America

Top 10 TED Talks for Entrepreneurs

Best TED Talks on Education

25 Most Dangerous Places to Live in America

Top 10 Ski Resorts in the United States – 2014 List

Top 10 Most Remote Places in the World

Most Visited Museums in the United States

Wealthiest Photographers in the World

Most Famous Gay Athletes

The World’s Most Famous Circuses

Best Hair Stylists

Most Popular NASCAR Drivers

The Best Romance Movies of all Time

The Most Wanted Drug Lords

The Oldest Money Managers

The Greatest Directors in the World

Largest Animals in the World

World’s Most Expensive Desserts

Best Selling Comic Books of All Time

A-list Actors who Sabotaged Their Career

Rappers With a College Degree

The Best Jazz Albums of all Time

The Most Influential Jazz Musicians

The World’s Most Famous Photographers

The Best Oscar-Winning Songs

Most Influential Choreographers Ever

Most Expensive Department Stores in the World

The Most Expensive Stolen Paintings in the World

The World’s Most Expensive Teas

Top Oscar Record Holders

The Most Expensive Flowers in the World

Countries With a Booming Film Industry

Most Expensive Cupcakes in the World

Uncommon European Escapes

The Most Stolen Artists in History

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!